Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity

Journal of Controlled Release

Volumn 105, Issue 1-2, 2005, Pages 89-105

  Dos Santos, Nancy ^a,b   Waterhouse, Dawn ^a   Masin, Dana ^a   Tardi, Paul G ^c   Karlsson, Göran ^b,d   Edwards, Katarina ^b,d   Bally, Marcel B ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Celator Technologies Inc   (Canada)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cryo transmission electron microscopy; Idarubicin; Liposomes; pH gradient; Remote loading

Indexed keywords

CONCENTRATION (PROCESS); DRUG PRODUCTS; ESTERS; LIPIDS; PHARMACOKINETICS; PLASMAS; TUMORS;

IDARUBUCIN; LIPOSOMES; MULTIDRUG RESISTANCE; THERAPEUTIC ACTIVITY;

CHOLESTEROL;

DISTEAROYLGLYCEROPHOSPHATIDYLCHOLINE; DISTEAROYLGLYCEROPHOSPHATIDYLETHANOLAMINE; IDARUBICIN; LIPOSOME; MACROGOL 2000; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG RELEASE; ENCAPSULATION; LEUKEMIA; MOUSE; NONHUMAN; OSMOSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; AREA UNDER CURVE; BUFFERS; CELL LINE, TUMOR; CELL SURVIVAL; CHOLESTEROL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; IDARUBICIN; LIPOSOMES; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; POLYETHYLENE GLYCOLS; TETRAZOLIUM SALTS; THIAZOLES; TRANSPLANTATION, HETEROLOGOUS; VEHICLES;

EID: 20444396580     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.03.007     Document Type: Article

References (47)

1. A.A. Gabizon Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes Cancer Res. 52 1992 891 896
2. D.W. Northfelt, F.J. Martin, P. Working, P.A. Volberding, J. Russell, M. Newman, M.A. Amantea, and L.D. Kaplan Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma J. Clin. Pharmacol. 36 1996 55 63
3. P.S. Gill, J. Wernz, D.T. Scadden, P. Cohen, G.M. Mukwaya, J.H. von Roenn, M. Jacobs, S. Kempin, I. Silverberg, G. Gonzales, M.U. Rarick, A.M. Myers, F. Shepherd, C. Sawka, M.C. Pike, and M.E. Ross Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma J. Clin. Oncol. 14 1996 2353 2364
4. A. Casazza, A. Di Marco, G. Bonadonna, V. Bonfante, C. Bertazzoli, O. Bellini, G. Pratesi, L. Sala, and L. Ballerini Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor acitivity and toxicity of daunorubicin and doxorubicin S. Crooke S. Reich Anthracyclines: Current Status and New Developments 1980 Academic Press Inc. New York 403 430
5. F. Arcamone, L. Bernardi, P. Giardino, B. Patelli, A. Marco, A.M. Casazza, G. Pratesi, and P. Reggiani Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers Cancer Treat. Rep. 60 1976 829 834
6. M.M. Ames, and F. Spreafico Selected pharmacologic characteristics of idarubicin and idarubicinol Leukemia 6 1992 70 75
7. A.M. Casazza Experimental evaluation of anthracycline analogs Cancer Treat. Rep. 63 1979 835 844
8. E. Willmore, F. Errington, M.J. Tilby, and C.A. Austin Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells Biochem. Pharmacol. 63 2002 1807 1815
9. M. Limonta, A. Biondi, G. Giudici, G. Specchia, C. Catapano, G. Masera, T. Barbui, and M. D'Incalci Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells Cancer Chemother. Pharmacol. 26 1990 340 342
10. D.D. Ross, L.A. Doyle, W. Yang, Y. Tong, and B. Cornblatt Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance Biochem. Pharmacol. 50 1995 1673 1683
11. M.J. Kuffel, J.M. Reid, and M.M. Ames Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture Cancer Chemother. Pharmacol. 30 1992 51 57
12. D.J. Roovers, M. van Vliet, A.C. Bloem, and H.M. Lokhorst Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines Leuk. Res. 23 1999 539 548
13. R. Testi, L. Mattii, D. Di Simone, L. Zaccaro, G. Malvaldi, B. Grassi, and M. Petrini Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines Leuk. Res. 19 1995 257 261
14. E. Berman, and M. McBride Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells Blood 79 1992 3267 3273
15. P.H. Wiernik, P.L. Banks, D.C. Case Jr., Z.A. Arlin, P.O. Periman, M.B. Todd, P.S. Ritch, R.E. Enck, and A.B. Weitberg Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 79 1992 313 319
16. E. Berman, G. Heller, J. Santorsa, S. McKenzie, T. Gee, S. Kempin, S. Gulati, M. Andreeff, J. Kolitz, and J. Gabrilove Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 77 1991 1666 1674
17. A. Martoni, E. Piana, M. Guaraldi, G. Cilenti, A. Farris, F. Saccani, G. Becchi, and F. Pannuti Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer Oncology 47 1990 427 432
18. M. Broggini, C. Italia, T. Colombo, L. Marmonti, and M.G. Donelli Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors Cancer Treat. Rep. 68 1984 739 747
19. S. Penco, A.M. Casazza, G. Franchi, B. Barbieri, O. Bellini, A. Podesta, G. Savi, G. Pratesi, C. Geroni, A. Di Marco, and F. Arcamone Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines Cancer Treat. Rep. 67 1983 665 673
20. L. Gallois, M. Fiallo, A. Laigle, W. Priebe, and A. Garnier-Suillerot The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids Eur. J. Biochem. 241 1996 879 887
21. H.S. Mulder, H. Dekker, H.M. Pinedo, and J. Lankelma The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity Biochem. Pharmacol. 50 1995 967 974
22. N. Dos Santos, L.D. Mayer, S.A. Abraham, R.C. Gallagher, K.A. Cox, P.G. Tardi, and M.B. Bally Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes Biochim. Biophys. Acta 1561 2002 188 201
23. F. Olson, C.A. Hunt, F.C. Szoka, W.J. Vail, and D. Papahadjopoulos Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes Biochim. Biophys. Acta 557 1979 9 23
24. J.T. Derksen, H.W. Morselt, and G.L. Scherphof Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages Biochim. Biophys. Acta 931 1987 33 40
25. L.D. Mayer, M.B. Bally, and P.R. Cullis Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient Biochim. Biophys. Acta 857 1986 123 126
26. T.E. Redelmeier, L.D. Mayer, K.F. Wong, M.B. Bally, and P.R. Cullis Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients Biophys. J. 56 1989 385 393
27. M. Almgren, K. Edwards, and J. Gustafsson Cryo-transmission electron microscopy of thin vitrified samples Curr. Opin. Colloid Interface Sci. 1 1996 270 278
28. M.B. Bally, R. Nayar, D. Masin, M.J. Hope, P.R. Cullis, and L.D. Mayer Liposomes with entrapped doxorubicin exhibit extended blood residence times Biochim. Biophys. Acta 1023 1990 133 139
29. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
30. M.C. Alley, D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker, and M.R. Boyd Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay Cancer Res. 48 1988 589 601
31. B.L. Mui, P.R. Cullis, E.A. Evans, and T.D. Madden Osmotic properties of large unilamellar vesicles prepared by extrusion Biophys. J. 64 1993 443 453
32. J.A. Shabbits, and L.D. Mayer P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs Mol. Cancer Ther. 1 2002 205 213
33. L.D. Mayer, L.C. Tai, D.S. Ko, D. Masin, R.S. Ginsberg, P.R. Cullis, and M.B. Bally Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice Cancer Res. 49 1989 5922 5930
34. L.D. Mayer, R. Nayar, R.L. Thies, N.L. Boman, P.R. Cullis, and M.B. Bally Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia Cancer Chemother. Pharmacol. 33 1993 17 24
35. M.S. Webb, T.O. Harasym, D. Masin, M.B. Bally, and L.D. Mayer Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models Br. J. Cancer 72 1995 896 904
36. H.J. Lim, D. Masin, N.L. McIntosh, T.D. Madden, and M.B. Bally Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors J. Pharmacol. Exp. Ther. 292 2000 337 345
37. K. Hashizaki, H. Taguchi, C. Itoh, H. Sakai, M. Abe, Y. Saito, and N. Ogawa Effects of poly(ethylene glycol) (PEG) chain length of PEG-lipid on the permeability of liposomal bilayer membranes Chem. Pharm. Bull. (Tokyo) 51 2003 815 820
38. A.R. Nicholas, M.J. Scott, N.I. Kennedy, and M.N. Jones Effect of grafted polyethylene glycol (PEG) on the size, encapsulation efficiency and permeability of vesicles Biochim. Biophys. Acta 1463 2000 167 178
39. K. Edwards, M. Johnsson, G. Karlsson, and M. Silvander Effect of polyethyleneglycol-phospholipids on aggregate structure in preparations of small unilamellar liposomes Biophys. J. 73 1997 258 266
40. C. Allen, N. Dos Santos, R. Gallagher, G.N. Chiu, Y. Shu, W.M. Li, S.A. Johnstone, A.S. Janoff, L.D. Mayer, M.S. Webb, and M.B. Bally Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol) Biosci. Rep. 22 2002 225 250
41. K. Sou, T. Endo, S. Takeoka, and E. Tsuchida Poly(ethylene glycol)-modification of the phospholipid vesicles by using the spontaneous incorporation of poly(ethylene glycol)-lipid into the vesicles Bioconjug. Chem. 11 2000 372 379
42. P.S. Uster, T.M. Allen, B.E. Daniel, C.J. Mendez, M.S. Newman, and G.Z. Zhu Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time FEBS Lett. 386 1996 243 246
43. T. Bogush, and J. Robert Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells Anticancer Res. 16 1996 365 368
44. S. Bennis, P. Faure, C. Chapey, Y.P. Hu, J. Fourche, J. El Yamani, and J. Robert Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin Anticancer Drugs 8 1997 610 617
45. A.M. Deffie, T. Alam, C. Seneviratne, S.W. Beenken, J.K. Batra, T.C. Shea, W.D. Henner, and G.J. Goldenberg Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and-resistant P388 leukemia Cancer Res. 48 1988 3595 3602
46. J.P. McPherson, A.M. Deffie, N.R. Jones, G.A. Brown, K.L. Deuchars, and G.J. Goldenberg Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha Anticancer Res. 17 1997 4243 4252
47. S.A. Abraham, K. Edwards, G. Karlsson, S. MacIntosh, L.D. Mayer, C. Mckenzie, and M.B. Bally Formation of transition metal-doxorubicin complexes inside liposomes Biochim. Biophys. Acta 1565 2002 41 54